DB Life Insurance has become the latest Korean life insurer to secure temporary exclusive selling rights for a cancer product built around artificial intelligence, entering a segment where larger rivals moved months earlier and where a new financial-sector AI rulebook took effect weeks before its launch.
The company said on July 6 that the Korea Life Insurance Association’s new-product review committee granted its “(Non-participating) AI Life Care Cancer Insurance” a three-month exclusive usage right, according to The Asia Business Daily. The product links an individual health grade directly to premium discounts and combines enrolment and post-enrolment health management in a single service, with an “AI Health Coaching Service” as a central feature, the report said. DB Life said it developed the underlying generative AI in-house, shaped the service during development using a consumer panel, and tested it through an internal trial group.
Oh Hyunjung, head of the New Growth task force at DB Life, described the product’s aim in remarks reported by The Asia Business Daily. “This product is designed so that AI precisely assists customers in health management and ensures that their efforts to maintain good health translate into tangible benefits such as reduced insurance premiums,” Oh said.
The exclusive usage right, described in the Korean market as a temporary patent, is granted by the insurance associations to products judged to show originality and usefulness, according to Seoul Economic Daily. During the grant period, competing insurers may not sell an equivalent product.
Grant lengths have been extended to spur product development. Financial authorities widened the range from three-to-12 months to six-to-18 months in the second half of 2025, Seoul Economic Daily reported. Before that change, only one product across the life and non-life sectors had received 12-month exclusivity, the outlet said. In 2026, Shinhan Life’s tontine pension insurance and a pregnancy-support benefit under Hanwha General Insurance’s women’s health product each received 12-month rights, while riders from Hanwha Life and Kyobo Life each received six months, according to the same report. DB Life’s three-month term sits at the lower end of the scale.
Applications have risen sharply. Domestic insurers filed 31 applications for exclusive rights in the third quarter of 2025, a 138% increase from 13 a year earlier, surpassing the full-year totals of 26 in 2024 and 19 in 2023, according to the General Insurance Association of Korea as reported by Korea Bizwire. Recent grants have spanned dementia-assessment coverage, pet insurance, and a policy reimbursing transport costs during subway delays, the outlet reported.
The commercial value of a short grant has limits. Seoul Economic Daily reported that one insurer holding six-month exclusivity sold only dozens of policies, citing an industry view that agents avoid selling products with complex structures. “When products are too complex, agents avoid selling them – that’s the dilemma,” an industry official said in remarks reported by the outlet.
DB Life’s launch follows comparable moves by larger competitors in the same product line. Hanwha Life introduced an AI-powered cancer insurance plan in September 2025 in partnership with the health care start-up Need, offering coverage alongside an AI system providing cancer prevention, treatment, and recovery information, The Korea Herald reported. “The new insurance plan goes beyond providing simple coverage upon cancer diagnosis, offering customized protection to customers through Need’s AI-powered Cancer Protection System,” a Hanwha Life official said in remarks reported by the Herald.
Samsung Life, Kyobo Life, and Hanwha Life, South Korea’s three largest life insurers by premium, have all been expanding their use of AI, including in underwriting, claims processing and customer-facing services. Hanwha Life separately used AI document processing to structure roughly five million historical claims for cancer-product design, according to a case study published by vendor Upstage. The broader South Korean life and non-life market is projected to grow from US$190.0 billion in 2025 to $197.47 billion in 2026, Mordor Intelligence reported, with insurers pivoting toward protection-type products amid an aging population.
The product cluster is forming as Korea moves to formalize supervision of AI in finance. The Financial Services Commission’s (FSC) AI guidelines for the financial sector took effect June 22, 2026, applying to all financial companies across seven areas including governance, human supervision, and data and model credibility. Under the human-supervision principle, AI is treated as an assistive tool, with final decision-making authority resting with a human supervisor, a requirement that carries operational weight for insurers using AI in underwriting and claims. The framework is currently self-regulatory, but the FSC has signalled it is an interim step.
The guidelines follow the AI Basic Act, which took effect Jan. 22, 2026, and which the law firm Kim & Chang described as setting governance and compliance standards for AI while promoting innovation. Products that tie verified health data to pricing sit at the intersection of these frameworks and Korea’s personal-data rules. Life insurers face particular scrutiny when AI draws on sensitive health data, as RNA Analytics noted that the long-term consequences of such decisions bring rules comparable to Article 22 of the European Union’s General Data Protection Regulation into play, requiring clear explainability and consent protocols.
Products that price on individual health data raise a question that runs deeper than compliance. Research published in The Geneva Risk and Insurance Review found that when data-driven classification is inexpensive, insurers have an incentive to adopt maximal granularity, treating each subpopulation as a separate risk class. The same body of research has noted that the datafication of insurers’ processes can disrupt the traditional characteristics of distribution and solidarity, particularly in health insurance. Behaviour-linked pricing that converts individual health grades into premium discounts sits directly on that tension, between the efficiency of finely identifying individual risk and the pooling function on which insurance rests.
Global survey data indicates the industry remains cautious about deeper AI deployment. A GlobalData poll conducted across the first and second quarters of 2026, covering 113 respondents, found close to one-quarter viewed AI as not ready for broad use in insurance, the firm reported. “Regulation has not fully caught up yet and there is concern around who is liable for mistakes made by AI,” said Ben Carey-Evans, senior insurance analyst at GlobalData.
DB Life’s three-month exclusivity will lapse in October 2026, after which competitors may offer comparable products. Whether behaviour-linked pricing tied to AI-generated health grades draws closer regulatory attention under the FSC’s human-supervision and data-credibility principles remains to be seen.
